Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash & Equivalents (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Cash & Equivalents for 11 consecutive years, with $64.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 7.16% year-over-year to $64.9 million, compared with a TTM value of $64.9 million through Sep 2025, down 7.16%, and an annual FY2024 reading of $89.4 million, down 52.66% over the prior year.
  • Cash & Equivalents was $64.9 million for Q3 2025 at Spyre Therapeutics, down from $80.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $235.4 million in Q2 2023 and bottomed at $14.6 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $76.6 million, with a median of $46.8 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents tumbled 83.19% in 2021, then soared 545.67% in 2024.
  • Year by year, Cash & Equivalents stood at $15.1 million in 2021, then skyrocketed by 130.24% to $34.9 million in 2022, then skyrocketed by 441.82% to $188.9 million in 2023, then crashed by 52.66% to $89.4 million in 2024, then dropped by 27.43% to $64.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for SYRE at $64.9 million in Q3 2025, $80.0 million in Q2 2025, and $46.8 million in Q1 2025.